Barclays
CRBU icon

Barclays’s Caribou Biosciences CRBU Stock Holding History

Barclays’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$165K Buy
129,962
+79,650
+158% +$124K ﹤0.01% 4073
2026
Q2 		$88.5K Buy
50,312
+23,599
+88% +$46.6K ﹤0.01% 4096
2026
Q1 		$50.8K Buy
26,713
+5,025
+23% +$8.62K ﹤0.01% 4318
2025
Q4 		$34.5K Sell
21,688
-84
-0.4% -$176 ﹤0.01% 4796
2025
Q3 		$50.7K Buy
21,772
+84
+0.4% +$159 ﹤0.01% 4763
2025
Q2 		$27.3K Sell
21,688
-82,720
-79% -$81.4K ﹤0.01% 4802
2025
Q1 		$95.3K Sell
104,408
-41,009
-28% -$53.3K ﹤0.01% 4428
2024
Q4 		$231K Buy
145,417
+15,578
+12% +$31.3K ﹤0.01% 4237
2024
Q3 		$254K Buy
129,839
+71,463
+122% +$146K ﹤0.01% 4177
2024
Q2 		$95.7K Sell
58,376
-38,857
-40% -$124K ﹤0.01% 3929
2024
Q1 		$500K Sell
97,233
-166,238
-63% -$1.03M ﹤0.01% 3594
2023
Q4 		$1.51M Buy
263,471
+9,240
+4% +$45.7K ﹤0.01% 3137
2023
Q3 		$1.22M Buy
254,231
+236,020
+1,296% +$1.46M ﹤0.01% 2188
2023
Q2 		$77.4K Sell
18,211
-82,981
-82% -$373K ﹤0.01% 3660
2023
Q1 		$537K Sell
101,192
-18,899
-16% -$118K ﹤0.01% 3222
2022
Q4 		$754K Buy
120,091
+36,690
+44% +$326K ﹤0.01% 3030
2022
Q3 		$880K Buy
83,401
+80,692
+2,979% +$752K ﹤0.01% 2331
2022
Q2 		$15K Sell
2,709
-5,660
-68% -$43.3K ﹤0.01% 4499
2022
Q1 		$77K Buy
+8,369
New +$88.2K ﹤0.01% 3910

Other funds holding CRBU

Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays's CRBU Position: Q3 2026 in Review

Barclays increased its Caribou Biosciences (CRBU) stake by 158% in Q3 2026, buying an estimated $124K and bringing the position to 129,962 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #4073.

Barclays first reported a position in CRBU in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.51M in Q4 2023. 71 funds tracked by Wall St. Rank hold CRBU as of Q3 2026.

  • Barclays held 129,962 shares of Caribou Biosciences worth $165K as of Q3 2026.
  • Barclays bought 79,650 Caribou Biosciences shares in Q3 2026, an estimated $124K.
  • Caribou Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4073 holding.
  • Barclays first reported a position in Caribou Biosciences in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Caribou Biosciences position peaked at $1.51M in Q4 2023.
  • 71 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.